|
Hims doesn’t plan to be the first to offer peptides, opting instead to take time building out the product line. "I think when we step back, we believe that we've got a combination of things, the brand, the infrastructure and ultimately the capabilities to really be a leader in this emerging category as the regulatory path becomes more clear in July,” CEO Andrew Dudum said in Hims’ first-quarter earnings call on Monday.
That comes after the FDA in April said it plans to reclassify at least a dozen peptides, with a key advisory committee meeting slated for July. The Hims execs said they believe the telehealth company’s advantage lies in the compounding pharmacies it owns. |